Page last updated: 2024-11-12

azacosterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Azacosterol: Diaza derivative of cholesterol which acts as a hypocholesteremic agent by blocking delta-24-reductase, which causes the accumulation of desmosterol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10023199
CHEMBL ID1615357
SCHEMBL ID219117
MeSH IDM0002057

Synonyms (27)

Synonym
imd 760
azacosterol
androst-5-en-3-ol, 17-((3-(dimethylamino)propyl)methylamino)-, (3-beta,17-beta)-
azacosterol [inn]
azacosterolum [inn-latin]
17-beta-((3-(dimethylamino)propyl)methylamino)androst-5-en-3-beta-ol
androst-5-en-3-beta-ol, 17-beta-((3-(dimethylamino)propyl)methylamino)-
androst-5-en-3-ol, 17-((3-(dimethylamino)propyl)methylamino)-, (3beta,17beta)-
20,25-diazacholesterol
diazasterol
313-05-3
CHEMBL1615357
unii-ept876j73a
ept876j73a ,
azacosterolum
SCHEMBL219117
azacosterol [mi]
17.beta.-((3-(dimethylamino)-propyl)methylamino)androst-5-en-3.beta.-ol
androst-5-en-3-ol, 17-((3-(dimethylamino)propyl)methylamino)-, (3.beta.,17.beta.)-
DTXSID1058509
AC-22386
AKOS025401578
Q4832015
(3s,8r,9s,10r,13s,14s,17s)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
(3| cent,17|a)-17-[[3-(dimethylamino)propyl]methylamino]-androst-5-en-3-ol
(3beta,17beta)-17-[[3-(dimethylamino)propyl]methylamino]-androst-5-en-3-ol
(3,17)-17-[[3-(dimethylamino)propyl]methylamino]-androst-5-en-3-ol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Rats were given a single subcutaneous injection of SC-12937 at a dosage of 100 or 200 mg/kg body weight and were killed on days 2 or 10 post-injection."( Effect of 22,25-diazacholesterol dihydrochloride on the spermatogenesis of a wild rat, Bandicota bengalensis.
Hikim, AP,
)
0.13
" The identification of an analyte in blood which was highly correlated with absorbed dose and efficacy is valuable for determining effective formulations and dosing variables."( Desmosterol: a biomarker for the efficient development of 20,25-diazacholesterol as a contraceptive for pest wildlife.
Furcolow, CA; Goldade, DA; Goodall, MJ; Johnston, JJ; Kimball, BA; Miller, LA; Yoder, CA, 2003
)
0.32
" In both dosage groups, only 11-12% of the seminiferous tubules were affected, and no significant differences were found in the frequency of affected tubules between the two groups."( Antispermatogenic and antifertility effects of 20,25-diazacholesterol dihydrochloride in mice.
Chakravarty, S; Singh, SK,
)
0.13
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID540238Phospholipidosis-positive literature compound observed in mouse
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (81.63)18.7374
1990's2 (4.08)18.2507
2000's4 (8.16)29.6817
2010's3 (6.12)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.79%)6.00%
Case Studies1 (1.79%)4.05%
Observational0 (0.00%)0.25%
Other54 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]